TNFRSF17 and hematologic disorder: The other 2—Idecabtagene vicleucel and Ciltacabtagene autoleucel—target B-cell maturation antigen (BCMA), a protein expressed by both malignant and normal plasma cells.14 While CAR-T cell therapy has shown promising results in hematologic malignancies, it has not been without adverse effects.15 Cytokine release syndrome (CRS) is the most common of the adverse effects experienced among patients.16 CRS ranges from flu-like symptoms, such as fever, hypotension, myalgias, and arthralgias, to multi-organ dysfunction.